Therapy of hepatitis C in thalassemia: The influence of iron on achieving sustained viral response

Annals of Hematology

Volumn 89, Issue 2, 2010, Pages 215-216

  Alavian, Seyed Moayed ^a   Tabatabaei, Seyed Vahid ^a  

^a BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

IRON; IRON CHELATING AGENT; PEGINTERFERON; RIBAVIRIN; ANTIVIRUS AGENT; INTERFERON;

CLINICAL TRIAL; DRUG RESPONSE; DRUG SAFETY; GENOTYPE; HEPATITIS C; HUMAN; IRON METABOLISM; IRON OVERLOAD; LETTER; LIVER CIRRHOSIS; PHLEBOTOMY; PRIORITY JOURNAL; THALASSEMIA; BLOOD; METABOLISM; VIROLOGY;

ANTIVIRAL AGENTS; HEPATITIS C; HUMANS; INTERFERONS; IRON; RIBAVIRIN; THALASSEMIA;

EID: 74049147933     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-009-0785-8     Document Type: Letter

References (12)

1. Taher AT et al (2009) Hepatitis C antiviral response in thalassemia: what is the role of liver iron concentration? Ann Hematol. doi:10.1007/s00277-009- 0713-y.
2. Gehrke SG et al (2003) Hemochromatosis and transferrin receptor gene polymorphisms in chronic hepatitis C: impact on iron status, liver injury and HCV genotype. J Mol Med 81(12):780-787. doi:10.1007/s00109-003-0493-0.
3. Desai TK et al (2008) Phlebotomy improves therapeutic response to interferon in patients with chronic hepatitis C: a meta-analysis of six prospective randomized controlled trials. Dig Dis Sci 53 (3):815-822. doi:10.1007/s10620-007-9945-7.
4. Fontana RJ et al (2000) Iron reduction before and during interferon therapy of chronic hepatitis C: results of a multicenter, randomized, controlled trial. Hepatology 31(3):730-736. doi:10.1002/hep.510310325.
5. Olynyk JK et al (1995) Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C. Gastroenterology 108(4):1104-1109. doi:10.1016/0016-5085(95) 90209-0.
6. Sievert W et al (2002) Hepatic iron overload does not prevent a sustained virological response to interferon-alpha therapy: a long term follow-up study in hepatitis C-infected patients with beta thalassemia major. Am J Gastroenterol 97(4):982-987.
7. Spiliopoulou I et al (1999) Response to interferon alfa-2b therapy in mutitransfused children with beta-thalassemia and chronic hepatitis C. Eur J Clin Microbiol Infect Dis 18(10):709-715. doi:10.1007/s100960050383.
8. Artan R et al (2005) Interferon alpha monotherapy for chronic hepatitis C viral infection in thalassemics and hemodialysis patients. J Chemother 17(6):651-655.
9. Syriopoulou Vet al (2005) Sustained response to interferon alpha-2a in thalassemic patients with chronic hepatitis C. A prospective 8-year follow-up study. Haematologica 90(1):129-131.
10. Telfer PT et al (1997) Combination therapy with interferon alpha and ribavirin for chronic hepatitis C virus infection in thalassaemic patients. Br J Haematol 98(4):850-855. doi:10.1046/j.1365-2141.1997.2953112.x.
11. Harmatz P et al (2008) Safety and efficacy of pegylated interferon alpha-2a and ribavirin for the treatment of hepatitis C in patients with thalassemia. Haematol Hematol J 93(8):1247-1251. doi:10.3324/haematol.12352.
12. Fargion S et al (1997) Liver iron influences the response to interferon alpha therapy in chronic hepatitis C. Eur J Gastroenterol Hepatol 9(5):497-503.